Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.91 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.91 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.91 |
| ▸ | HPGD | P15428 | 3/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.91 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.91 |
| ▸ | APEX1 | P27695 | 1/20 | 0.91 |
| ▸ | HTR2B | P41595 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575897 | 0.95 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL674970 | 0.95 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9189819 | 0.91 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31543696 | 0.91 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1773582 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL342256 | 0.85 | MTNR1A (0.82) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL342184 | 0.84 | MTNR1A (0.79) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8041780 | 0.83 | MTNR1A (0.83) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8053222 | 0.82 | MTNR1A (0.81) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1772618 | 0.82 | HTR2B (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122072275-A | Detection of biomarkers in biological samples | 奥特森斯诊断有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20100120887-A1 | SUSTAINED RELEASE FORMULATION OF MELATONIN | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-05-13 | — | — | US | claimed |
| CN-122072275-A | Detection of biomarkers in biological samples | 奥特森斯诊断有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026104861-A1 | IODBR1 AND DERIVATIVES THEREOF FOR TREATING SLEEP DISORDERS | PHYTOQUEST LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-20250107560-A1 | CHRONOBIOLOGICAL FOOD FOR INFANTS AND METHOD FOR PRODUCING SAME | PADITZ EKKEHART (DE) | 2025-04-03 | — | — | US | disclosed |
| EP-4463011-A1 | CHRONOBIOLOGICAL FOOD FOR INFANTS AND METHOD FOR PRODUCING SAME | Paditz, Ekkehart (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-116699003-B | Circadian rhythm body fluid marker combination and UPLC-MS/MS detection method thereof | 中国民用航空局民用航空医学中心 | 2023-12-26 | — | — | CN | disclosed |
| CN-116699003-A | Circadian rhythm body fluid marker combination and UPLC-MS/MS detection method thereof | 中国民用航空局民用航空医学中心 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023135228-A1 | CHRONOBIOLOGICAL FOOD FOR INFANTS AND METHOD FOR PRODUCING SAME | PADITZ EKKEHART (DE) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134856-A1 | INFANT FOOD AND METHOD FOR PRODUCING SAME | PADITZ EKKEHART (DE) | 2023-07-20 | — | — | WO | disclosed |
| EP-4019017-A1 | COMPOSITION COMPRISING MELATONIN, PIPERINE AND VITAMIN D, CONTROLLED-RELEASE FORMULATION AND USE THEREOF FOR THE TREATMENT OF SLEEP DISORDERS | Uriach Consumer Healthcare, S.L. (ES) | 2022-06-29 | — | — | EP | disclosed |
| US-20020068692-A1 | Method for the treatment of neurological or neuropsychiatric disorders | CLARENCEW PTY LTD. ORGANIZED UNDER THE LAW OF AUSTRIALIA (AU) | 2002-06-06 | — | — | US | disclosed |
| EP-1189613-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS | Clarencew Pty Ltd. (AU) | 2002-03-27 | — | — | EP | disclosed |
| US-6310085-B1 | SUBJECTING PATIENT WITH DISORDER ASSOCIATED WITH ALTERED DOPAMINE FUNCTION TO THERAPY WHICH BLOCKS AND/OR INHIBITS MELATONIN, PRECURSORS THEREOF AND/OR METABOLIC PRODUCTS THEREOF | CLARENCEW PTY LTD. (AU) | 2001-10-30 | — | — | US | disclosed |
| US-6235719-B1 | CONTROLLING SLEEP CYCLE | LABORATOIRE OENOBOL, S.A. (FR) | 2001-05-22 | — | — | US | disclosed |
| WO-2000059504-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS | CLARENCEW PTY LTD (AU) | 2000-10-12 | — | — | WO | disclosed |
| EP-1032833-A2 | USE OF OXIDATIVE STRESS DIAGNOSTIC PLOT AS A HEALTH INDICATOR | Nikken Foods Co., Ltd. (JP) | 2000-09-06 | — | — | EP | disclosed |
| EP-0964679-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS | Clarencew Pty Ltd. (AU) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999063341-A2 | USE OF OXIDATIVE STRESS DIAGNOSTIC PLOT AS A HEALTH INDICATOR FOR ASSESSING OXIDATIVE STRESS AND ITS CONTROL IN HUMANS | NIKKEN FOODS CO., LTD. (JP) | 1999-12-09 | — | — | WO | disclosed |
| WO-1998015267-A1 | METHOD FOR THE TREATMENT OF NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS | CLARENCEW PTY LTD (AU) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068692-A1 | Method for the treatment of neurological or neuropsychiatric disorders | COMT, HNMT, PNMT | MTNR1A 7/4885MTNR1B 6/4885CYP1A2 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.